Roche Puts Up $1.65B to Partner With Zealand on ‘Future Foundational Therapy’ for Obesity
Posted
Frank Vinluan (via MedCity News)
Roche will share in developing and commercializing petrelintide, a clinical-stage Zealand Pharma drug that activates the amylin receptor to spark weight loss. This agreement represents the highest total financial consideration in the obesity field to date.
The post Roche Puts Up $1.65B to Partner With Zealand on ‘Future Foundational Therapy’ for Obesity appeared first on MedCity News.
